Chris Schelling

Chris Schelling is a seasoned leader in the biopharmaceutical industry, currently serving as Co-Founder and Board Member of Stealth Biopharmaceutical Company since December 2023, and as a Member of the Board of Trustees at Carroll College, where the individual chairs the Advancement Committee. Previously, Chris founded and led Acer Therapeutics Inc. as CEO until its acquisition by Zevra Therapeutics in November 2023, and founded Censa Pharmaceuticals Inc., which was acquired by PTC Therapeutics in June 2020. Additionally, Chris has held key positions at BioMarin Pharmaceutical Inc., Abgenix, Inc., and Cell Therapeutics, Inc., along with early career roles at Stanford Research Institute and Organon. Chris holds a BA in Biology (Pre-med) and History from Carroll College.